Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

      Date of Report (Date of earliest event reported): September 29, 2003

                           APPLIED DNA SCIENCES , INC.

             (Exact name of registrant as specified in its charter)

            Nevada                         2 90519                59-2262718
----------------------------             ----------          -------------------
(State or other jurisdiction             Commission            (IRS Employer
       of Incorporation)                 File Number         Identification No.)

       9225 Sunset Boulevard Los Angeles, CA            90069
     ----------------------------------------         ----------
     (Address of principal executive offices)         (Zip Code)

       Registrant's Telephone Number, including area code: (310) 246-1720

         (Former name or former address, if changed since last report.)

Item 5.  Other Information

On September 29, 2003, Applied DNA Sciences, Inc. (the "company",  "we", "us" or
"our")  announced  its first  international  sublicense  for the United  Kingdom
territory.  Applied DNA  Sciences,  Inc. , Biowell  Technology,  Inc.  and G. A.
Corporate  Finance Ltd.  entered into a Sub-License  Agreement in exchange for a
one time nonrefundable  discounted franchise fee of $3,000,000.  G. A. Corporate
Finance  Ltd's.  initial  payment of $25,000 was due upon the  execution  of the
Agreement  on August 27, 2003,  and the  remaining  $2,975,000  is subject to an
interest bearing promissory note,  payable in twenty (20) consecutive  quarterly
installments  of  Principal  and  Interest  in the amount  equal to the lower of
$185,937.50  or 35% of Gross  Revenues  for that quarter due on the final day of
the quarter.

We provide  security  solutions for the  protection  of corporate,  personal and
intellectual property from counterfeit and fraud by utilizing a proprietary line
of DNA  embedded-biotechnology  products.  Its  products  and  services  will be
offered to  corporations  and government  agencies and will be accompanied  with
monitoring and enforcement support.

Applied DNA Sciences,  Inc. has an exclusive licensing and partnership agreement
with Biowell  Technology,  Inc. of Taiwan. Our initial territories include North
America  and  Europe.  We are  positioned  to be the  market  leader  in  sales,
marketing, and sub-licensing of the DNA products developed by Biowell Technology
in the world's largest markets.

It is our intention to seek alliances with existing anti-counterfeit networks in
each market and to train  these  networks  to use our  technology  to detect and
monitor  counterfeit  and fraud,  using our own  anti-counterfeit  and  security
experts  to  help  detect  counterfeiting   attempts  against  corporations  and
government agencies.

Exhibit List

10.3     Exclusive Sub License Agreement, United Kingdom


Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                  APPLIED DNA SCIENCES, INC.

                                  /s/ Lawrence C. Lee
                                  Lawrence C. Lee
                                  President and Chief Executive Officer